Prostate Cancer

Pharma company receives marketing authorization for Plenaxis in Germany

Published in Medical Letter on the CDC and FDA, October 30th, 2005

Praecis Pharmaceuticals Incorporated (PRCS) announced that it has received marketing authorization for Plenaxis (abarelix 100 mg powder for an injectable suspension) from the German competent authority, Bundesinstitut fur Arzneimittel und Medizinprodukte (BfArM).

In Germany, Plenaxis is indicated to initiate hormonal castration in patients with advanced or metastatic, hormone-dependent prostate cancer, if androgen suppression is appropriate.

Praecis also announced that it received notice from Schering AG of Germany that it was exercising its right to terminate the parties' license, supply and distribution agreement due to Praecis not having received...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-10-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry